Sai Life Sciences Ltd. – Company Overview

→ Leading Contract Research, Development and Manufacturing Organization (CRDMO). → Partners with 280+ global pharmaceutical and biotechnology companies. → Specializes in new chemical entity (NCE) small-molecule drug discovery, development and manufacturing. → Expertise across synthetic and medicinal chemistry, biology, DMPK, toxicology and computational chemistry. → Operates across India, the UK, the USA and Japan, with a strong focus on quality and regulatory compliance. → R&D and manufacturing facilities in Hyderabad and Bidar have received USFDA Establishment Inspection Reports (EIRs). Financial & Fundamental Analysis → Operating Revenue: ₹2,250.36 Cr (TTM). → Revenue Growth: 29% annually, indicating strong growth. → Pre-tax Margin: 21%, reflecting healthy profitability. → ROE: 14%, indicating reasonable returns on shareholders’ capital. → Debt-to-Equity: 1%, suggesting low financial leverage. Technical Analysis → Trading close to its 50-day moving average (50 DMA). → Comfortably above its 200-day moving average (200 DMA), approximately 28% higher. → The 50 DMA is a key support level to monitor. → Technical View: Holding support near the 50 DMA could sustain the upward momentum, while a decisive breakdown may indicate near-term weakness. Disclaimer: For informational and educational purposes only. This is not investment advice or a recommendation to buy or sell securities.